مقایسهٔ روش‌ها

	کارآزمایی بالینی فاز سوم عملگرایانه	آزمایش تصادفی کنترل‌شده (RCT)
حوزه	اپیدمیولوژی	طراحی آزمایش
خانواده	Process / pipeline	Hypothesis test
سال پیدایش	1967 (Schwartz & Lellouch); formalized further in 2000s–2010s	1948
پدیدآور	Schwartz & Lellouch (distinction between pragmatic and explanatory trials)	James Lind (early precursor, 1747); modern formulation: Austin Bradford Hill & Medical Research Council (1948)
نوع	Randomized controlled trial design	Interventional comparative study
منبع بنیادین	Thorpe, K. E., Zwarenstein, M., Oxman, A. D., Treweek, S., Furberg, C. D., Altman, D. G., ... & Chalkidou, K. (2009). A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers. Journal of Clinical Epidemiology, 62(5), 464–475.	Schulz, K.F., Altman, D.G., Moher, D., for the CONSORT Group (2010). CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. BMJ, 340, c332.
نام‌های دیگر	pragmatic RCT, effectiveness trial, real-world RCT, pragmatic trial	RCT, randomised controlled trial, clinical trial, Randomize Kontrollü Çalışma (RCT) Tasarımı
مرتبط	2	7
خلاصه	A pragmatic phase III clinical trial is a large-scale randomized study designed to evaluate whether an intervention works under the conditions of everyday clinical practice rather than the tightly controlled environment of an explanatory efficacy trial. It recruits a broad, representative patient population, allows flexibility in treatment delivery, and measures outcomes that matter to patients and health systems, generating evidence directly applicable to real-world treatment decisions.	A randomized controlled trial (RCT) is the gold standard experimental design in clinical and health research, in which participants are randomly allocated to a treatment group or a control group so that the effect of an intervention can be measured with the highest possible degree of internal validity. The modern parallel-group RCT was formalized by Austin Bradford Hill and the Medical Research Council in their landmark streptomycin trial of 1948, and its reporting is governed today by the CONSORT 2010 guidelines (Schulz et al., 2010).